Biocytogen Enters into Antibody Agreement with Merck
BEIJING, CHINA, [April 29, 2022] – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced that it has entered into an evaluation and option agreement with Merck…
Read more
Biocytogen Signs RenMab™/RenLite® Licensing Agreement with BeiGene
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") reached an agreement with BeiGene (Beijing) Co., Ltd. ("BeiGene") (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen’s fully…
Read more
PEGSBoston 2022
Speaker: Dr. Qingcong Lin, CEO, Biocytogen Boston Corporation, Biocytogen Boston Corp Time: 9:30 am EDT, May 2nd Talk title: Generation of Fully Human Antibodies for…
Read more
Biocytogen Enters Agreement With CtM Bio to Co-develop TCR-Mimic Antibody-Based Multi-Specific T cell Engagers
BEIJING and SHANGHAI, April 18, 2022/PRNewswire/--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as "Biocytogen") announced a collaboration agreement with CtM Biotech (Shanghai) Co., Ltd…
Read more
Webinar: Generation and discovery of high affinity antibodies
Our webinar “Generation and discovery of high affinity antibodies” was live on April 27, 2022 at 1PM EDT. In this webinar, we will Introduce Biocytogen’s…
Read more
Biocytogen Subsidiary Eucure Biopharma Completes First Patient Dosing for Phase I Clinical Trial of YH003 (Anti-CD40 mAb) Triple Combination Therapy
BEIJING, April 6, 2022 - Biocytogen subsidiary Eucure Biopharma announced the first patient dosing for a phase I clinical trial (No. YH003005) of YH003 (anti-CD40…
Read more
Biocytogen Expands Global Footprint with the Opening of Biocytogen Europe Innovation Center in Germany
Beijing, China and Heidelberg, Germany, March 28, 2022 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as “Biocytogen”) announced the opening of the Biocytogen…
Read more
AACR 2022
Attend the meeting Our Poster Session Talk to us at booth 1043! The AACR Annual Meeting is the focal point of the cancer research…
Read more
Experimental Biology 2022
Talk to us at booth 830! Experimental Biology (EB) is the annual…
Read more
Biocytogen Subsidiary, Eucure Biopharma, Announces the First Patient Dosing for a Phase I Multi-regional Clinical Trial of YH002 (Anti-OX40 mAb) in Combination with YH001 (Anti-CTLA-4 mAb) in Australia
BEIJING, CHINA, March 8, 2022 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I multi-regional clinical trial…
Read more